Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Novartis (NYSE: NVS ) said in a press release that Tasigna, a drug currently in development that targets a form of leukemia, seems to treat the disease more effectively than the company's existing medication, Glivec -- sold as Gleevec in the United States.
The company said two-year data from its research indicates that patients who showed evidence of chronic myeloid leukemia after being treated with Glivec had undetectable levels following a switch to the new drug. Novartis characterized its findings as "statistically significant".
The company will launch a clinical trial early next year to ascertain whether patients showing positive results will be able to stop treatment entirely after a certain period of time.
Glivec will lose patent exclusivity in 2015.